Treatment with the Src/Abl inhibitor dasatinib, used against chronic myeloid leukaemia, can result in superficial oedema and pleural, pericardial or ascites effusions in a third of patients (43, 44). The gene discussed is SRC; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.